ScreenPoint puts $16M toward Transpara breast AI expansion
The funding will support product development and international expansion of ScreenPoint Medical’s Transpara breast AI solutions.
ScreenPoint Medical has raised $16M to support product development and international expansion of its Transpara breast AI solutions.
The funding includes $14M from existing investors Insight Partners and Siemens Healthineers. The company also reported $2M in non-dilutive research grants.
ScreenPoint said Transpara Breast AI is deployed in more than 30 countries and has processed more than 12M mammograms to date. The software is CE-marked and FDA-cleared for 2D and 3D mammography, according to the company.
The announcement follows recent research milestones for the platform. Final results from the MASAI randomized controlled trial were published in The Lancet in January. ScreenPoint said the trial found consistently favorable outcomes compared with standard double reading, including effects on cancer detection and workload reduction.
A separate prospective study published in Nature Medicine evaluated AI-based triage and decision support in mammography and digital breast tomosynthesis. The study reported a 63.6% lower radiologist workload and a 15.2% higher cancer detection rate under the AI strategy.
In npj Digital Medicine, researchers compared 4 breast cancer risk prediction algorithms using 112,621 negative mammograms from 2 UK NHS Breast Screening Programme sites. Within the highest 14% of risk scores, the top algorithm identified 41.8% of future cancers and 50.3% of interval cancers.
ScreenPoint said its image-based risk algorithm outperformed Mirai, iCAD, and Google at 5-year risk prediction. The company noted that the risk algorithm is for investigational use only.
The company said the new capital will support product innovation, international expansion, and strategic initiatives for breast cancer detection and risk assessment.
Company:ScreenPoint
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Niowave breaks ground on $75M Ac-225 production facility
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
GE HealthCare, UW Medicine launch imaging research collaboration
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Radnostix reports 27% Q1 revenue decline
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Plus Therapeutics signs AI deal with Ephemeral
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm launches balloon-less EBUS bronchoscope
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST wins FDA clearance for Pro Diagnostic System
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.
Braid Health launches $199 radiology second-opinion service
Patients can upload MRI, CT, X-ray, or ultrasound files and receive a written second opinion from a board-certified U.S. radiologist.
QT Imaging prices $10M public offering
QT Imaging Holdings priced a $10M underwritten public offering of common stock and pre-funded warrants. The breast imaging technology company plans to use proceeds for working capital and general corporate purposes.
PSMA PET guidance anchors EDAP-Telix HIFU prostate work
EDAP TMS and Telix Pharmaceuticals signed a letter of intent to explore clinical research combining Focal One Robotic HIFU with Telix PSMA PET imaging agents in prostate cancer care.
UnitedHealthcare cites radiology costs in Maryland premium request
UnitedHealthcare is seeking an average 7.9% mid-year premium increase for some Maryland small-group plans. The insurer cited rising outpatient costs, including radiology, lab pathology, infusion, and radiation therapy.
Lumexa adds 4 imaging centers, including first UPMC JV site
Lumexa Imaging added 4 outpatient imaging centers across Pennsylvania, North Carolina, South Carolina, and Florida. The expansion includes acquired centers through joint ventures with UPMC and Advocate Health, plus 2 newly built locations.
PAI report finds 82% of U.S. physicians are now employed
A new PAI-Avalere report found that 82% of U.S. physicians are employed by hospitals, health systems, or corporate entities. Physician-owned settings now account for 18% of physicians and 36.1% of practices.